CD276 anticorps (AA 100-300)

N° du produit ABIN7869825

L’anticorps anti-CD276 Monoclonal Souris est utilisé pour la détection de CD276 dans des échantillons de Humain. Il a été validé pour IHC (p).

Aperçu rapide pour CD276 anticorps (AA 100-300) (ABIN7869825)

Antigène: CD276

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CD276 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: B7H3-4345

Détail du produit anti-CD276 anticorps

Épitope: AA 100-300

Fonction: CD276 Antibody / B7-H3

Purification: Protein A/G affinity

Immunogène: A portion of amino acids 100-300 from the human CD276 protein was used as the immunogen for the CD276 antibody.

Isotype: IgG1, kappa

Information d'application

Indications d'application: Optimal dilution of the CD276 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the CD276 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur CD276

Antigène: CD276

Autre désignation: CD276

Sujet: T cell activation and immune function are regulated by the innate immune system through positive and negative costimulatory molecules. One such molecule, B7-H3 (B7-homolog 3, also designated B7RP-2 and CD276) belongs to the B7 immunoglobulin superfamily. Soluble B7-H3/CD276 binds a putative receptor on activated T-cells that is distinct from CD28, CTLA-4, ICOS and PD-1. Widely expressed on nonlymphoid tissues, it costimulates proliferation of both CD4+ and CD8+ T cells. The ability of B7-H3/CD276 to stimulate Th1 and cytotoxic-T cell responses suggest that it may have antitumor activity. B7-H3 interactions may play a role in regulating cell-mediated immune responses against cancer, implicating B7-H3/CD276 as a potential therapeutic tool.

UniProt: Q5ZPR3

Pathways: Cancer Immune Checkpoints